Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Table 2 Adjusted mean difference from baseline (mean) and standard error (SE) of total cholesterol (TC), LDL-cholesterol (LDL), total cholesterol/HDL-cholesterol ratio (TC/HDL) and triglycerides (TG) one year after the switch

Switch		TC T2 - TC T0 (mg/dl)		LDL T2 - LDL T0 (mg/dl)		HDL T2 - HDL T0 (mg/dl)		TC/HDL T2 - TC/HDL T0 (mg/dl)		TG T2 - TG T0 (mg/dl)		FRS T2 - FRS T0
From	To	mean (±SE)	p*	mean (±SE)	p*	mean (±SE)	p*	mean (±SE)	p*	mean (±SE)	p*	mean (±SE)	p§
2 NRTI + EFV	DTG	−15.0 ± 6.5	.0210	− 10.9 ± 6.2	.0771	−1.4 ± 1.8	.4222	− 0.21 ± 0.21	.3242	− 19.6 ± 15.2	.1992	0.67 ± 0.71	0.35
	EVG	1.7 ± 8.6	.8401	− 5.9 ± 8.0	.4623	2.8 ± 2.4	.2350	− 0.32 ± 0.27	.2488	27.2 ± 20.5	.1853	0.74 ± 0.92	0.42
	RPV	−31.6 ± 5.3	<.0001	−21.0 ± 5.0	<.0001	− 2.9 ± 1.4	.0421	− 0.52 ± 0.17	.0021	−31.5 ± 12.4	.0116	0.03 ± 0.38	0.93
2 NRTI + PI/r	DTG	−16.8 ± 5.9	.0049	−8.8 ± 5.7	.1247	2.4 ± 1.6	.1335	− 0.60 ± 0.19	.0015	−26.1 ± 14.0	.0628	− 0.54 ± 0.60	0.36
	EVG	−16.6 ± 5.8	.0044	− 12.0 ± 5.6	.0312	3.0 ± 1.6	.0604	− 0.63 ± 0.18	.0007	−23.0 ± 16.6	.0926	−0.87 ± 0.52	0.10
	RPV	− 20.7 ± 5.2	<.0001	−13.6 ± 5.0	.0064	0.00 ± 1.4	.9995	− 0.52 ± 0.17	.0021	− 28.2 ± 12.2	.0216	−0.25 ± 0.48	0.60

NRTI nucleoside reverse transcriptase inhibitors; EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine, T0 baseline, T2 one year follow up. Significant p values (p < 0.05) are indicated by bold font
*Adjustment for age, sex, baseline value of the analyzed variable, time on antiretroviral therapy, diabetes and use of statin
§ Adjustment for baseline value of FRS and time on antiretroviral therapy

ISSN: 1471-2334